Avadel Pharma (NASDAQ: AVDL) reported Q4 EPS of $0.00, $0.30 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $43.1 million versus the consensus estimate of $34.95 million.

• Total revenues for fourth quarter and full year 2016 were $43.1 million and $150.2 million, compared to $44.6 million and $173.0 million in the prior year periods.
• GAAP net income for the fourth quarter was $4.7 million, or $0.11 per diluted share, compared to GAAP net income of $73.5 million, or $1.69 per diluted share, during the same period last year. GAAP net loss for the full year 2016 was $41.3 million or $1.00 per diluted share compared to GAAP net income of $41.8 million or $0.96 per diluted share during the same period last year.
• Adjusted net income for the fourth quarter was $0.1 million, or $0.00 per diluted share, compared to an adjusted net income of $10.8 million, or $0.25 per diluted share, during the same period last year. (1)
• Cash and marketable securities at December 31, 2016 were $154.2 million, up from $149.7 million, at September 30, 2016 and $144.8 million at December 31, 2015.

GUIDANCE:

Avadel Pharma sees FY2017 EPS of $0.20-$0.35, versus the consensus of $0.18. Avadel Pharma sees FY2017 revenue of $170-200 million, versus the consensus of $171.93 million.

For earnings history and earnings-related data on Avadel Pharma (AVDL) click here.